Navigation Links
DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Date:9/26/2007

Multinational Trial to Evaluate Safety, Efficacy of Novel Cortisol

Inhibitor

SAN FRANCISCO, Sept. 26 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that it has begun dosing patients in a Phase 2b clinical trial of DIO-902, a novel cortisol synthesis inhibitor being studied for the treatment of type 2 diabetes mellitus (T2DM).

The Phase 2b multinational trial is a randomized, placebo-controlled, double-blinded study designed to evaluate the safety and efficacy of DIO-902 and to determine dosing for pivotal Phase 3 clinical studies. The primary efficacy endpoint being evaluated is the change in HbA1c, a key measurement of glycemic control, compared to placebo. Secondary endpoints include the change in total and LDL-cholesterol, and the change in blood pressure. Top line data from the trial is expected by the second half of 2008.

"The rollout of this multinational, multicenter trial demonstrates DiObex's ability to launch a major clinical program for the treatment of metabolic disease," CEO David Cory said. "With treatments for both type 1 and type 2 diabetes in mid-stage clinical study and additional indications under evaluation for DIO-902, DiObex is well positioned to move a strong pipeline of product candidates into the advanced stages of development."

The trial is being conducted at 20 centers across the United States, Australia and New Zealand. Approximately 200 patients will be treated for 16 weeks. Patients who are already on a stable dose of metformin will be randomized to receive placebo or one of three doses of DIO-902 once daily for 16 weeks, with the option of continuing on an open label extension for an additional six months of treatment.

Preclinical and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance
'/>"/>

SOURCE DiObex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
2. Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... N.J. , July 24, 2014 IGI ... Jersey based specialty generic pharmaceutical company, today ... from its Board of Directors.  Mr. Finio has accepted ... and under the terms of his acceptance of his ... in his role as Director for IGI Laboratories, Inc.  ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... Use, OD Deaths Increase (7/20), Michigan has seen a nearly ... four years. While the count was 271 between 1999 and ... range. DEA Agents believe that, like other states, drug users ... the drug via prescription pills. He compared the price of ...
(Date:7/25/2014)... The Little Gym of Houston will attend the ... at Discovery Green in downtown Houston. The eleven ... Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire and their ... to be attending and performing at the Family Fun ... Sugarland-Missouri City location. “We believe in the message and ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Art of Facial ... services to those in Toronto who are looking for minor ... study done by the American Academy of Facial Plastic ... 2014, interest in facial plastic surgery showed a surprising increase ... rose 10 percent, while hair transplants increased by 7 percent ...
(Date:7/25/2014)... Port Washington, NY (PRWEB) July 25, 2014 ... to protecting the rights of consumers comments on a ... the widow of a smoker $23.6 billion in punitive ... which manufactures Kool brand cigarettes. The case is Cynthia ... in 2008 in the Florida First Circuit Court, Escambia ...
(Date:7/25/2014)... 25, 2014 Hastings and Hastings, ... attorney’s fees with regard to personal injury claims, announces ... wide range of legal services for those that have ... another individual or corporation. Free initial consultation services gives ... of a potential personal injury claim . It ...
Breaking Medicine News(10 mins):Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 2Health News:Art of Facial Surgery Responds to Demand for Facial Plastic Surgery Increase Due to the Popularity of Selfies 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... Decision A Day Keeps the Doctor Away - Using QlikView, Inside ... such as tracking the progression of diseases in the community through ... Australia healthy." said Jon Marshall, Managing Director, asteRx. , ... ...
... Exam event is highly successful in pairing veterinary ophthalmologists with service dogs ... ... 2009 -- She has been blind for 13 years. So, when ... Service Dog Eye Exam event , she was elated. She completely ...
... leaders in diagnosing and treating Lyme disease, has launched a new website ... treatment and cure of this highly debated disease. , ... Havertown, PA ... launched a new web site today that is dedicated to giving advanced, ...
... BLUD ), a global leader in providing ... announced that it will release its fiscal 2010 guidance ... The Company will host a conference call on Tuesday, ... discuss the results. Investors are invited to participate ...
... Quarter on Cost CuttingWAYNE, Pa., May 19 ... a full service multinational contract research organization (CRO) that ... and patient registries to many of the world,s leading ... first quarter ended March 31, 2009. Net revenue ...
... Pa., May 19 The Quigley Corporation, (Nasdaq: ... it has uncovered additional facts with respect to the relationship between Ted ... that were uncovered:, , ... $55,000 to Dr. Rosenbloom. Karkus is, and has been, a shareholder ...
Cached Medicine News:Health News:Innovative Business Intelligence Software Helps Keep Australia Healthy this Winter 2Health News:Innovative Business Intelligence Software Helps Keep Australia Healthy this Winter 3Health News:More Than 1,500 Service Dogs Receive Free Sight Saving Eye Exams 2Health News:More Than 1,500 Service Dogs Receive Free Sight Saving Eye Exams 3Health News:More Than 1,500 Service Dogs Receive Free Sight Saving Eye Exams 4Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 2Health News:Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease 3Health News:Encorium Reports First Quarter 2009 Financial Results 2Health News:Encorium Reports First Quarter 2009 Financial Results 3Health News:Encorium Reports First Quarter 2009 Financial Results 4Health News:Encorium Reports First Quarter 2009 Financial Results 5Health News:Encorium Reports First Quarter 2009 Financial Results 6Health News:Encorium Reports First Quarter 2009 Financial Results 7Health News:Encorium Reports First Quarter 2009 Financial Results 8Health News:Encorium Reports First Quarter 2009 Financial Results 9Health News:Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders 2Health News:Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders 3Health News:Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders 4
Great for small incisions and excision needs...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
2.5mm...
... with 12 bevel tip; silicone ... bevel is opposite curve, Designed ... fluid, Sleeve acts as stop ... minimize chance of trauma to ...
Medicine Products: